Shares in 4DMedical Ltd (ASX: 4DX) jumped more than 8% in early trade after the company said a study validating its key technology had been published in a prestigious journal.
Image source: Getty Images
Strong endorsement
4DMedical said in a statement to the ASX that a study evaluating its technology, CT:VQ, had been published in the American Journal of Respiratory and Critical Care Medicine – the world's leading respiratory medicine journal.
The company went on to say:
The study included patients with severe emphysema undergoing bilateral lung volume reduction surgery (LVRS) and analysed pre‑operative non‑contrast inspiratory and expiratory CT scans using quantitative imaging techniques, including CT‑derived perfusion (CT:VQ). The authors conclude that integrating functional data from CT:VQ perfusion and anatomical (emphysema) information from routine CT imaging can enhance and streamline patient selection for LVRS, increasing successful outcomes from 48% to 76%, with potential to reduce reliance on additional perfusion imaging studies and improve clinical outcomes.
4DMedical said its technology was designed to integrate into routine radiology workflows and "can analyse historical CT scans, enabling functional assessment earlier in the care pathway, including during LVR patient selection discussions''.
The company added:
LVRS is a specialised surgical intervention typically performed at advanced medical centres (AMCs). Efficient identification of suitable candidates is critical, as outcomes are strongly influenced by underlying lung physiology, including the distribution of emphysema and regional perfusion. By improving pre‑operative selection, functional CT‑based assessment has the potential to reduce unnecessary invasive procedures and optimise utilisation of high‑value surgical respiratory services.
4DMedical said hospital margins from LVRS were highly sensitive to patient selection, and its technology directly enhances LVRS economics by enabling earlier, non-invasive identification of optimal candidates.
The company added:
By reducing reliance on additional imaging, avoiding low‑value surgical interventions and improving post‑operative outcomes, functional CT imaging supports higher procedural success rates, more efficient use of surgical infrastructure and improved contribution margins per case, reinforcing LVRS as a precision‑led, high‑value service line for advanced medical centres.
The company is also presenting the data at the ATS International Conference 2026 in Orlando, Florida, which is being held this week.
Shares fluctuating
While 4DMedical shares have retraced from highs around $6.80 in mid-April, shareholders in the company are still sitting on gains of more than 1000% for the past 12 months.
The shares traded as high as $4.35 early on Tuesday, up 8.7%, before sliding to be 1.8% lower at $3.93, with 3.2 million shares traded.
The company is valued at $2.38 billion.
